The Pill, a drug used to treat depression and anxiety, may also be a treatment for dementia, a team of scientists say.
The researchers say they have found that when given in combination with another drug known as olanzapine, the Pill helps people who are suffering from cognitive impairment or dementia to regain a sense of control over their lives.
olanzerapine is a non-opioid opioid medication, which has been shown to help people with Alzheimer’s disease, Parkinson’s disease and other forms of dementia.
They have tested the pill in patients with mild cognitive impairment, Alzheimer’s and Parkinson’s and found that it helped to reduce the symptoms of the diseases.
The pill works by preventing the production of glutamate by the brain. “
We’ve shown that the combination of olva-prazopamine and olvaprazopine helps people to regain control over some of their daily activities, such as managing their finances and eating well.” olvadapine works by blocking the release of the opioid receptor that is involved in a variety of mental disorders, including schizophrenia, and also inhibits the release in the brain of the neurotransmitter glutamate, which can be used to cause a number of brain disorders.
The pill works by preventing the production of glutamate by the brain.
Dr Cuddonsons team found that olvanzapines combination of medication, olvabol, and olivabol were able to help with some of the symptoms that people who were suffering from Alzheimer’s had been having.
It is hoped that the new drug will be used in conjunction with other medications to help control the symptoms and improve the quality of life for those suffering from dementia.
Dr Chris White, an associate professor of psychiatry at the University of Sydney, said: ”These findings could pave the way for the development of olanzbol, a more appropriate treatment for patients with dementia.”
Olvavax is also a new drug, which is not being tested for use in humans, but Dr White said it had been used in people with mild dementia.
The researchers have now published their results in the journal PLOS ONE.
The study is part of a larger effort to find new drugs to treat dementia.